Accéder au contenu
Merck

MafA-Controlled Nicotinic Receptor Expression Is Essential for Insulin Secretion and Is Impaired in Patients with Type 2 Diabetes.

Cell reports (2016-02-26)
Elvira Ganic, Tania Singh, Cheng Luan, João Fadista, Jenny K Johansson, Holly Ann Cyphert, Hedvig Bennet, Petter Storm, Gaëlle Prost, Henrik Ahlenius, Erik Renström, Roland Stein, Leif Groop, Malin Fex, Isabella Artner
RÉSUMÉ

Monoamine and acetylcholine neurotransmitters from the autonomic nervous system (ANS) regulate insulin secretion in pancreatic islets. The molecular mechanisms controlling neurotransmitter signaling in islet β cells and their impact on diabetes development are only partially understood. Using a glucose-intolerant, MafA-deficient mouse model, we demonstrate that MAFA controls ANS-mediated insulin secretion by activating the transcription of nicotinic (ChrnB2 and ChrnB4) and adrenergic (Adra2A) receptor genes, which are integral parts of acetylcholine- and monoamine-signaling pathways. We show that acetylcholine-mediated insulin secretion requires nicotinic signaling and that nicotinic receptor expression is positively correlated with insulin secretion and glycemic control in human donor islets. Moreover, polymorphisms spanning MAFA-binding regions within the human CHRNB4 gene are associated with type 2 diabetes. Our data show that MAFA transcriptional activity is required for establishing β cell sensitivity to neurotransmitter signaling and identify nicotinic signaling as a modulator of insulin secretion impaired in type 2 diabetes.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-α2A Adrenergic Receptor antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution